The MNKD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MNKD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The MNKD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View MNKD Detailed Price Forecast - CNN Money||View MNKD Detailed Summary - Google Finance|
|View MNKD Detailed Summary - Yahoo! Finance||View MNKD Stock Research & Analysis - Zacks.com|
|View MNKD Trends & Analysis - Trade-Ideas||View MNKD Major Holders - Barrons|
|View MNKD Call Transcripts - NASDAQ||View MNKD Breaking News & Analysis - Seeking Alpha|
|View MNKD Annual Report - CompanySpotlight.com||View MNKD OTC Short Report - OTCShortReport.com|
|View MNKD Fundamentals - TradeKing||View MNKD SEC Filings - Bar Chart|
|View Historical Prices for MNKD - The WSJ||View Performance/Total Return for MNKD - Morningstar|
|View the Analyst Estimates for MNKD - MarketWatch||View the Earnings History for MNKD - CNBC|
|View the MNKD Earnings - StockMarketWatch||View MNKD Buy or Sell Recommendations - MacroAxis|
|View the MNKD Bullish Patterns - American Bulls||View MNKD Short Pain Metrics - ShortPainBot.com|
|View MNKD Stock Mentions - StockTwits||View MNKD Stock Mentions - PennyStockTweets|
|View MNKD Stock Mentions - Twitter||View MNKD Investment Forum News - Investor Hub|
|View MNKD Stock Mentions - Yahoo! Message Board||View MNKD Stock Mentions - Seeking Alpha|
|View Insider Transactions for MNKD - SECform4.com||View Insider Transactions for MNKD - Insider Cow|
|View MNKD Major Holdings Summary - CNBC||View Insider Disclosure for MNKD - OTC Markets|
|View Insider Transactions for MNKD - Yahoo! Finance||View Institutional Holdings for MNKD - NASDAQ|
|View MNKD Stock Insight & Charts - FinViz.com||View MNKD Investment Charts - StockCharts.com|
|View MNKD Stock Overview & Charts - BarChart||View MNKD User Generated Charts - Trading View|
Edited Transcript of MNKD earnings conference call or presentation 2-Aug-18 9:00pm GMT
Posted on Wednesday September 19, 2018
Q2 2018 MannKind Corp Earnings Call
Positive Afrezza® Clinical Data from STAT Study Published in Diabetes Technology & Therapeutics
Posted on Thursday September 13, 2018
WESTLAKE VILLAGE, Calif., Sept. 13, 2018-- MannKind Corporation announced today that "Improved Postprandial Glucose with Inhaled Technosphere ® Insulin Compared to Insulin Aspart in Patients with ...
Implied Volatility Surging for MannKind (MNKD) Stock Options
Posted on Monday September 10, 2018
MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.
Mannkind Afrezza Sales Have Doubled and Treprostinil is Getting Some Traction
Posted on Monday September 10, 2018
NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. On September 4th, MannKind announced that they have entered into a worldwide exclusive licensing and collaboration agreement for the development and commercialization of a dry powder formulation of treprostinil, an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. MNKD doubled its market share over the past year as a result of its commercialization efforts and are excited about its new Afrezza clinical data being released throughout 2018.